EDX Medical service agreement with Astron Health
EDX Medical Group plc has secured a new agreement to provide molecular profiling products and services to Astron Health Ltd in the UK. This partnership will involve EDX Medical supplying its Caris MI Profile™ and Caris Assure® diagnostic tests, which are designed to guide precision oncology and offer blood-based molecular profiling for patients where tissue biopsy is not feasible. The company views this collaboration as a validation of its strategy to deliver advanced diagnostic tests that inform treatment decisions and improve patient outcomes.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, announces that the Company has been appointed to provide molecular profiling products and services to Astron Health Ltd ("Astron"), a global oncology service providing precision oncology second opinions and molecular profiling interpretation.
Under the agreement with Astron, EDX Medical will provide in the UK a service and highly accurate diagnostic tests that include Caris MI Profile™, a comprehensive tumour profiling platform designed to guide precision oncology, and Caris Assure®, blood based comprehensive molecular profiling designed for patients with previously diagnosed solid tumours and where tissue biopsy is not feasible.
Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: "We are delighted that Astron, which operates globally, has chosen EDX Medical as the right partner in the UK to supply the most advanced and detailed cancer tests which are renowned for equipping oncologists and doctors with highly accurate molecular information to guide treatment decisions. We see this type of partnership as validation of our strategy to provide the world's best diagnostic tests that shape the treatment of major diseases and help save lives."
Dr Padman Vamadevan, co-founder and chief medical officer of Astron Health, commented: "As a company that provides precision oncology second opinions and molecular profiling interpretation for patients and doctors worldwide, it is essential that we have access to the best-in-class diagnostic tests that will inform clinicians and their patients. We are very pleased to have EDX Medical supplying a molecular profiling service in the UK."
Astron interprets molecular tumour profiling to help clinicians understand what is driving a patient's cancer. The company's molecular tumour board translate these findings into evidence-graded second opinions and management options for the primary clinical teams to consider.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.